E2F-1 overexpression sensitizes colorectal cancer cells to camptothecin

Cancer Gene Therapy

Volumn 10, Issue 3, 2003, Pages 168-178

  Dong, Yan Bin ^a   Yang, Hai Liang ^a   McMasters, Kelly M ^a,b  

^a UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

Adenovirus; Apoptosis; Camptothecin; E2F 1; Gene therapy; Topoisomerase I

Indexed keywords

ADENOVIRUS VECTOR; APHIDICOLIN; BETA GALACTOSIDASE; CAMPTOTHECIN; DNA; DNA TOPOISOMERASE; FAS ANTIGEN; FAS LIGAND; TRANSCRIPTION FACTOR E2F;

ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL ASSAY; CELL PROTECTION; CHEMOSENSITIVITY; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DISEASE MODEL; DNA REPLICATION; DOSE CALCULATION; DRUG SENSITIVITY; GENE TRANSFER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LETHAL DOSE; NUDE MOUSE; PRIORITY JOURNAL; TUMOR VOLUME; WESTERN BLOTTING; XENOGRAFT;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APHIDICOLIN; APOPTOSIS; CAMPTOTHECIN; CELL CYCLE; CELL CYCLE PROTEINS; CELL DIVISION; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DNA TOPOISOMERASES, TYPE I, EUKARYOTIC; DNA-BINDING PROTEINS; E2F TRANSCRIPTION FACTORS; E2F1 TRANSCRIPTION FACTOR; GENE THERAPY; GENES, P53; GENETIC VECTORS; HUMANS; MALE; MICE; MICE, INBRED BALB C; TRANSCRIPTION FACTORS;

ADENOVIRIDAE; MUS MUSCULUS;

EID: 0037344006     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700565     Document Type: Article

References (47)

1. Macdonald JS, Astrow AB. Adjuvant therapy of colon cancer. Semin Oncol. 2001;28:30-40.
2. Grivicich I, Mans DR, Peters GJ, et al. Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer. Braz J Med Biol Res. 2001;34:1087-1103.
3. Saltz L. Irinotecan-based combinations for the adjuvant treatment of stage III colon cancer. Oncology. 2000;14: 47-50.
4. Liu JR, Opipari AW, Tan L, et al. Dysfunctional apoptosome activation in ovarian cancer: implications for chemoresistance. Cancer Res. 2002;62:924-931.
5. Schmitt CA, Lowe SW. Apoptosis and chemoresistance in transgenic cancer models. J Mol Med. 2002;80:137-146.
6. Poulain L, Lincet H, Duigou F, et al. Acquisition of chemoresistance in a human ovarian carcinoma cell is linked to a defect in cell cycle control. Int J Cancer. 1998;78:454-463.
7. Lutzker SG, Levine AJ. Apoptosis and cancer chemotherapy. Cancer Treat Res. 1996;87:345-356.
8. Slichenmyer WJ, Rowinsky EK, Donehower RC, et al. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst. 1993;85:271-291.
9. Shimada Y, Yoshino M, Wakui A, et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol. 1993;11:909-913.
10. Gupta M, Abdel-Megeed M, Hoki Y, et al. Eukaryotic DNA topoisomerases mediated DNA cleavage induced by a new inhibitor: NSC 665517. Mol Pharmacol. 1995;48: 658-665.
11. Liu LF, Desai SD, Li TK, et al. Mechanism of action of camptothecin. Ann NY Acad Sci. 2000;922:1-10.
12. Avemann K, Knippers R, Koller T, et al. Camptothecin, a specific inhibitor of type I DNA topoisomerase, induces DNA breakage at replication forks. Mol Cell Biol. 1988;8: 3026-3034.
13. Horwitz SB, Horwitz MS. Effects of camptothecin on the breakage and repair of DNA during the cell cycle. Cancer Res. 1973;33:2834-2836.
14. Pommier Y, Leteurtre F, Fesen MR, et al. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest. 1994;12:530-542.
15. Hsiang YH, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 1989;49(18):5077-5082.
16. Goldwasser F, Bae I, Valenti M, et al. Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. Can Res. 1995;55:2116-2121.
17. Sugimoto Y, Tsukahara S, Oh-hara T, et al. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res. 1990;50:6925-6930.
18. Benedetti P, Fiorani P, Capuani L, et al. Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine. Cancer Res. 1993; 53:4343-4348.
19. Rubin E, Pantazis P, Bharti A, et al. Identification of a mutant human topoisomerase I with intact catalytic activity and resistance to 9-nitro-camptothecin. J Biol Chem. 1994; 269:2433-2439.
20. Girling R, Bandara LR, Ormondroyd E, et al. A new component of transcription factor DRTF1/E2F. Nature. 1993;362:83-87.
21. De Gregori J, Kowalik T, Nevins JR. Cellular targets for activation by the E2F-1 transcription factor include DNA synthesis and G1/S-regulatory genes. Mol Cell Biol. 1995;5: 4215-4224.
22. Hunt KK, Deng J, Liu TJ, et al. Adenovirus-mediated overexpresion of the transcription factor E2F-1 induces apoptosis in human breast and ovarian carcinoma cell lines and does not require p53. Cancer Res. 1997;57:4722-4726.
23. Fueyo J, Gomez-Manzano C, Yung WK, et al. Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo. Nat Med. 1998;4:685-690.
24. Dong YB, Yang HL, Elliott MJ, et al. Adenovirus-mediated E2F-1 gene transfer efficiently induces apoptosis in melanoma cells. Cancer 1999;86:2021-2033.
25. Yang HL, Dong YB, Elliott MJ, et al. Caspase activation and changes in Bcl-2 family member protein expression associated with E2F-1-mediated apoptosis in human esophageal cancer cells. Clin Cancer Res. 2000;6:1579-1589.
26. Yang HL, Dong YB, Elliott MJ, et al. Adenovirus-mediated E2F-1 gene transfer inhibits MDM2 expression and efficiently induces apoptosis in mdm2-overexpressing tumor cells. Clin Cancer Res. 1999;5:2242-2250.
27. Dong YB, Yang HL, Elliott MJ, et al. Adenovirus-mediated E2F-1 gene transfer sensitizes melanoma cells to apoptosis induced by topoisomerase II inhibitors. Cancer Res. 2002;62:1776-1783.
28. Yang HL, Dong YB, Elliott MJ, et al. Additive effect of adenovirus-mediated E2F-1 gene transfer and topoisomerase II inhibitors on apoptosis in human osteosarcoma cells. Cancer Gene Ther. 2001;8:241-251.
29. Meng RD, Phillips P, EL-Deiry WS. P53-independent increase in E2F-1 expression enhances the cytotoxic effects of etoposide and of adriamyicn. Int J Oncol. 1999;14:5-14.
30. Banerjee D, Schnieders B, Fu JZ, et al. Role of E2F-1 in chemosensitivity. Cancer Res. 1998;58:4292-4296.
31. Nip J, Strom DK, Lee BE, et al. E2F-1 cooperates with topoisomerase II inhibition and DNA damage to selectively augment p53-independent apoptosis. Mol Cell Biol. 1997; 17:1049-1056.
32. O'Connor DJ, Lu X. Stress signals induce transcriptionally inactive E2F-1 independently of p53 and RB. Oncogene. 2000;19:2369-2376.
33. Elliott MJ, Dong YB, Yang HL, et al. E2F-1 up-regulates c-Myc and p14(ARF) and induces apoptosis in colon cancer cells. Clin Cancer Res. 2001;7:3590-3597.
34. Goldwasser F, Shimizu T, Jackman J, et al. Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. Cancer Res. 1996;56: 4430-4437.
35. Jaks V, Joers A, Kristjuhan A, Maimets T. p53 protein accumulation in addition to the transactivation activity is required for p53-dependent cell cycle arrest after treatment of cells with camptothecin. Oncogene. 2001;20: 1212-1219.
36. Motwani M, Jung C, Sirotnak FM, et al. Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts. Clin Cancer Res. 2001;7: 4209-4219.
37. Waldman T, Zhang Y, Dillehay L, et al. Cell-cycle arrest versus cell death in cancer therapy. Na Med. 1997;3: 1034-1036.
38. Lamb JR, Friend SH. Which guesstimate is the best guesstimate? Predicting chemotherapeutic outcomes. Nat Med. 1997;3:962-963.
39. Wu X, Levine AJ. p53 and E2F-1 cooperate to mediate apoptosis. Proc Natl Acad Sci USA. 1994;91: 3602-3606.
40. Kowalik TF, DeGregori J, Schwarz JK, et al. E2F-1 overexpression in quiescent fibroblasts leads to induction of cellular DNA synthesis and apoptosis. J Virol. 1995;69: 2491-2500.
41. Hiebert SW, Packham G, Strom DK, et al. E2F-1: DP-1 induces p53 and overrides survival factors to trigger apoptosis. Mol Cell Biol. 1995;15:6864-6874.
42. Holmberg S, Helin K, Sehested M, et al. E2F-1-induced p53-independent apoptosis in transgenic mice. Oncogene. 1998;17:143-156.
43. Kuerbitz SJ, Plunkett BS, Walsh WV, et al. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA. 1992;89:7491-7495.
44. Shao RG, Cao CX, Nieves-Neira W, et al. Activation of the Fas pathway independently of Fas ligand during apoptosis induced by camptothecin in p53 mutant human colon carcinoma cells. Oncogene. 2001;20:1852-1859.
45. Giovanella BC, Hinz HR, Kozielski AJ, et al. Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin. Cancer Res. 1991; 51:3052-3055.
46. Jordan-Sciutto KL, Hall DJ. A mutant E2F-1 transcription factor that affects the phenotype of NIH3T3 fibroblasts inefficiency associates with cyclin A-cdk2. Biochem Cell Bio. 1998;76:37-44.
47. Chen AY, Liu LF. DNA tpoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol. 1994;34:191-218.